SMALL ANIMAL IMAGING FACILITY (SAIF) The mission of the Small Animal Imaging Facility (SAIF) is to advance cancer research by providing cancer center members with powerful imaging technologies and the expertise necessary to successfully integrate imaging sciences into preclinical cancer research. Dr. John D. Hazle serves as director, and Dr. James A. Bankson serves as co-director. The facility includes faculty experts, specially trained staff, and state-of-the-art imaging instrumentation, most of which is not available anywhere else in the cancer center. The SAIF has 3 separate sites across the campus to ensure convenient access to all cancer center members. SAIF imaging laboratories are located on the North Campus adjacent to and contiguous with the small animal vivarium, inside the South Campus Vivarium, and in South Campus Research Building #3. SAIF faculty and staff are available to support all aspects of imaging in preclinical cancer research, from proposal and experiment design through data acquisition, analysis, interpretation, and presentation. Currently, the SAIF has 21 unique pieces of imaging equipment optimized for small animals and a full complement of ancillary equipment for support of animals before, during, and after experiments. The imaging equipment includes 3 high-field magnetic resonance scanners, a low-field permanent magnet magnetic resonance scanner, a dynamic nuclear polarization system for generating hyperpolarized magnetic resonance agents, a microcomputed tomography system, a positron emission tomography/single-photon emission computed tomography/computed tomography scanner, 2 small- animal radiation research platforms, 2 ultrasound systems (1 capable of photoacoustic imaging), a dedicated photoacoustic imaging system, a cabinet X-Ray system, 6 optical imaging systems, and a prototype magnetic relaxometry system (on loan as part of a research agreement). During this grant period, MD Anderson has funded $5,918,344 in capital equipment, and approximately $1.1M has been obtained through NCI Shared or High-end Instrumentation grants. Annual operational funding is $195,521 (20%) from the CCSG, $719,742 (74%) from program income, and $53,413 (6%) of institutional support. During this 6-year grant period, the SAIF served a total of 250 cancer center members, including investigators from all 16 CCSG programs. A total of 87% of all usage was peer-review funded, and the SAIF is requesting $200,057 (20%) from the CCSG in grant Yr44. Overall use has increased 2.7-fold in Yr42 over the average use in the prior funding cycle. The SAIF supported 181 peer-reviewed publications during this reporting period, with 51 (28%) published in journals with IF >10 and 119 (66%) published in those with IF >5.
The specific aims are:
Aim 1 : To maintain a broad range of state-of-the-art imaging instrumentation and dedicated staff that support the preclinical imaging needs of cancer center members;
Aim 2 : To provide consultation, training and support in the planning, acquisition, and analysis of imaging data;
and Aim 3 : To develop and implement new technologies and methods that improve the accuracy and precision of quantitative imaging biomarkers in preclinical cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-44
Application #
9997798
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Dutcher, Giselle M A; Bilen, Mehmet Asim (2018) Therapeutic Vaccines for Genitourinary Malignancies. Vaccines (Basel) 6:
Kurnit, Katherine C; Dumbrava, Ecaterina E Ileana; Litzenburger, Beate et al. (2018) Precision Oncology Decision Support: Current Approaches and Strategies for the Future. Clin Cancer Res 24:2719-2731
Duplisea, Jonathan J; Mokkapati, Sharada; Plote, Devin et al. (2018) The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. World J Urol :
Jordan, V Craig (2018) Tamoxifen Resistance Trumped and Oral Selective Estrogen Receptor Degraders Arrive. Clin Cancer Res 24:3480-3482
Pantano, Naitielle; Hunt, Brady; Schwarz, Richard A et al. (2018) Is Proflavine Exposure Associated with Disease Progression in Women with Cervical Dysplasia? A Brief Report. Photochem Photobiol 94:1308-1313
Mehrvarz Sarshekeh, Amir; Xiong, Henry Q; Iizuka, Kenzo et al. (2018) Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer. Invest New Drugs 36:895-902
Lang, Frederick F; Conrad, Charles; Gomez-Manzano, Candelaria et al. (2018) Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. J Clin Oncol 36:1419-1427
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Talluri, Rajesh; Shete, Sanjay (2018) An approach to estimate bidirectional mediation effects with application to body mass index and fasting glucose. Ann Hum Genet 82:396-406
Bhadra, Anindya; Rao, Arvind; Baladandayuthapani, Veerabhadran (2018) Inferring network structure in non-normal and mixed discrete-continuous genomic data. Biometrics 74:185-195

Showing the most recent 10 out of 12418 publications